Ruxolitinib in polycythaemia vera: Hint of non-quantifiable added benefit

7 agosto 2015

Following review of Ruxolitinib in polycythaemia vera, patients complain of fatigue less frequently and have a better quality of life. The study design makes interpretation of the results difficult, however.
http://www.sciencedaily.com/releases/2015/08/150807110742.htm

Volver